In the past week, LPTX stock has gone down by -1.04%, with a monthly decline of -83.72% and a quarterly plunge of -84.43%. The volatility ratio for the week is 8.98%, and the volatility levels for the last 30 days are 13.07% for Leap Therapeutics Inc The simple moving average for the past 20 days is -61.49% for LPTX’s stock, with a -80.16% simple moving average for the past 200 days.
Is It Worth Investing in Leap Therapeutics Inc (NASDAQ: LPTX) Right Now?
The 36-month beta value for LPTX is at 0.32. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LPTX is 28.57M, and currently, shorts hold a 11.22% of that float. The average trading volume for LPTX on February 13, 2025 was 787.37K shares.
LPTX) stock’s latest price update
Leap Therapeutics Inc (NASDAQ: LPTX)’s stock price has dropped by -6.49 in relation to previous closing price of 0.54. Nevertheless, the company has seen a loss of -1.04% in its stock price over the last five trading days. prnewswire.com reported 2025-01-28 that 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
Analysts’ Opinion of LPTX
Many brokerage firms have already submitted their reports for LPTX stocks, with Robert W. Baird repeating the rating for LPTX by listing it as a “Neutral.” The predicted price for LPTX in the upcoming period, according to Robert W. Baird is $1.25 based on the research report published on January 29, 2025 of the current year 2025.
Rodman & Renshaw gave a rating of “Buy” to LPTX, setting the target price at $8 in the report published on June 28th of the previous year.
LPTX Trading at -78.66% from the 50-Day Moving Average
After a stumble in the market that brought LPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.47% of loss for the given period.
Volatility was left at 13.07%, however, over the last 30 days, the volatility rate increased by 8.98%, as shares sank -83.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.72% lower at present.
During the last 5 trading sessions, LPTX fell by -1.04%, which changed the moving average for the period of 200-days by -84.08% in comparison to the 20-day moving average, which settled at $1.3101. In addition, Leap Therapeutics Inc saw -82.45% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LPTX
Current profitability levels for the company are sitting at:
- -108.44 for the present operating margin
- 0.82 for the gross margin
The net margin for Leap Therapeutics Inc stands at -101.88. The total capital return value is set at -1.4. Equity return is now at value -106.79, with -87.23 for asset returns.
Based on Leap Therapeutics Inc (LPTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -146.72. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -79.67.
Currently, EBITDA for the company is -80.99 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of -68.0. The receivables turnover for the company is 0.81for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.97.
Conclusion
In conclusion, Leap Therapeutics Inc (LPTX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
